Dmitry Balyasny’s Phio Pharmaceuticals PHIO Stock Holding History

Dmitry Balyasny’s Portfolio PHIO Stock Details PHIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-93	Closed	-$6K	–	3129
2022 Q3	$6K	Buy	+93	New	+$7.04K	﹤0.01%	2693

Other funds holding PHIO

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Dmitry Balyasny's PHIO Position: Q4 2022 in Review

Dmitry Balyasny sold out of Phio Pharmaceuticals (PHIO) in Q4 2022, closing a stake of 93 shares — an estimated $6K sold.

Dmitry Balyasny first reported a position in PHIO in Q3 2022 and held it in 1 quarter. The position peaked at $6K in Q3 2022. 10 funds tracked by Wall St. Rank hold PHIO as of Q4 2022.

Dmitry Balyasny reported no remaining Phio Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Dmitry Balyasny sold 93 Phio Pharmaceuticals shares in Q4 2022, an estimated $6K.
Dmitry Balyasny first reported a position in Phio Pharmaceuticals in Q3 2022 and held it in 1 quarter.
Dmitry Balyasny's Phio Pharmaceuticals position peaked at $6K in Q3 2022.
10 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.